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What’s new? 
● HbA1c variability is known to be associated with mortality in Type 2 diabetes.
● This is the first study to show an association between HbA1c variability and mortality
in Type 1 diabetes.
● Our data also show an association between HbA1c variability and the combined end-
point of death or first admission to hospital.
● HbA1c variability could be a useful clinical marker of risk in people with Type 1
diabetes.
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Abstract 
Aim Despite evidence of morbidity, no evidence exists on the relationship between HbA1c 
variability and mortality in Type 1 diabetes. We performed an observational study to 
investigate whether the association between HbA1c variability and mortality exists in a 
population of people with Type 1 diabetes. As a secondary outcome, we compared onset of 
first hospital admission between groups. 
Methods People with Type 1 diabetes were identified for inclusion from the Scottish Care 
Information – Diabetes data set. This database includes data of all people known to have 
diabetes who live within Scotland. A survival analysis was carried out over a 47-month 
period comparing two groups; group 1 with a HbA1c coefficient of variation (CV) above the 
median CV value, and group 2 with a CV below the median value. Time to death or first 
admission was also analysed. A Cox proportional hazard model was used to compare time to 
death, adjusting for appropriate covariables. 
Results Some 6048 individuals with Type 1 diabetes were included in the analysis. Median 
HbA1c CV was 7.9. The hazard ratio (HR) for mortality for those with an HbA1c CV above 
the median value is 1.5 over 47 months of follow-up (P < 0.001). HR for survival to either 
the first admission to hospital or death for those with an HbA1c CV above the median value 
was 1.35 (95% confidence interval 1.25–1.45) over 730 days of follow-up (P < 0.001). 
Conclusion Our results show that people with greater HbA1c variability have a higher rate of 
mortality and earlier hospital admission in Type 1 diabetes. 
 
Introduction 
HbA1c is an essential measurement used in the management of Type 1 diabetes. The Diabetes 
Control and Complications Study (DCCT) showed that intensive glycaemic control as 
measured by HbA1c reduces microvascular complications [1]. Follow-up of this cohort 
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revealed that earlier lowering of HbA1c leads to a reduced incidence of cardiovascular 
disease, with the effect persisting for up to 30 years [2]. 
The term glucose variability can have multiple definitions. Most commonly it is thought of as 
the minute-to-minute and hour-to-hour changes in continuous glucose monitoring (CGM) or 
capillary blood glucose (CBG) testing which are used for real-time treatment decision-
making [3]. The term can also be used to describe variations of glucose from day-to-day or 
week-to-week [4]. 
One marker of longer term, month-to-month, glucose variability is fluctuation between HbA1c 
measures. In Type 2 diabetes greater HbA1c variability has been consistently associated with 
microvascular complications and linked with increased frequency of cardiovascular events 
and all-cause mortality, independent of baseline HbA1c [4–8]. For measurement of HbA1c 
variability, studies have either used a standard deviation (SD) or coefficient of variation (CV). 
Both SD and CV are measures of variability. SD measures how much values differ from the 
group mean, whereas CV is the ratio of SD to the mean. There is no agreed standardised 
method of measuring HbA1c variability [8]. 
In Type 1 diabetes the DCCT did not uncover an association between short-term glucose 
variability and increased risk of microvascular complications, as measured via SD [9,10]. By 
contrast, longer term HbA1c variability in Type 1 diabetes, also measured via SD, was shown 
to predict the development of retinopathy and nephropathy over and above the mean HbA1c 
value [10,11]. The DCCT used 3-monthly seven-point glucose profiles equivalent to 28 
finger-stick measurements per year, which may not have been enough data to adequately 
assess glycaemic variability. However, increased incidence of cardiovascular events has also 
been associated with increased HbA1c variability in Type 1 diabetes, with the magnitude of 
the impact proposed to be at least as high as that of mean HbA1c [11,12]. 
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Despite evidence of morbidity, no firm evidence exists of the relationship between HbA1c 
variability and mortality in Type 1 diabetes. We aimed to investigate whether the association 
exists in a population of people with Type 1 diabetes, as previously described in Type 2 
diabetes. As a secondary outcome, we also looked at onset of first hospital admission. 
 
Methods 
Patients coded as having Type 1 diabetes and appearing on 1 January 2013 in the Scottish 
Care Information Diabetes (SCI-Diabetes) data set in Greater Glasgow and Clyde were 
considered for inclusion. SCI-Diabetes is a database containing data for all people known to 
have diabetes living in Scotland. A diagnosis of diabetes at least 12 months prior to a 30-
month run-in period was required. This period was chosen to reduce the potential 
confounding effect of a likely sudden reduction of glucose immediately post diagnosis. All 
HbA1c measurements made during the run-in period were identified. The number of 
measurements made was recorded, along with the median HbA1c and CV of identified HbA1c 
measurements. The age of participants at 1 January 2013 was calculated; all included 
participants were >13 years old at this time point. 
Mortality data (date of death) were available within the SCI-Diabetes data set. Time of the 
first hospital admission post 1st January 2013 was inferred from the hospital CBG data set, 
comprising data from all eight hospitals in the health board area. CBG value, time of test, 
date of test and corresponding patient identifier was extracted from analysis of the Abbott 
Precision Webb system (Abbott, Maidenhead, UK). A hospital admission was defined as a 
patient with more than two CBG measurements undertaken within 5 days. CBG data were 
available to 5 January 2015. 
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Survival analysis 
To assess potential associations between HbA1c CV and mortality we used a proportional 
hazards regression (Cox) model. Potential confounding risk factors included were diabetes 
duration (years), median HbA1c during the run-in period, total number of HbA1c 
measurements made during run-in and age at 1 January 2013. The hazard ratio (HR) was used 
to estimate the relative risk of death during the follow-up period. Analysis was performed 
using the coxph function within the R package ‘survival’. 
 
Time to death or first admission 
A survival analysis (as described above) was performed over the period 1 January 2013 to 5 
January 2015, investigating time to the competing endpoints of either admission to hospital or 
death. Potential confounding risk factors included were diabetes duration (years), median 
HbA1c during the run-in period, total number of HbA1c measurements made during run-in and 
age at 1 January 2013. 
 
Results 
Some 6048 individuals with Type 1 diabetes were included in the analysis. Median HbA1c 
CV was 7.9 (interquartile range (IQR) 5.1–11.8). Characteristics of analysed groups above 
and below this median CV are shown in Table 1. 
 
Survival analysis 
The survival plot is shown in Fig. 1. HR for mortality for those with an HbA1c CV above the 
median value is 1.47 (95% confidence interval (CI) 1.27–1.67) over 1430 days of follow-up 
(P < 0.001). 
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Time to first hospital admission or death 
HR for survival to first hospital admission or death for those with an HbA1c IQR above the 
median value is 1.35 (95% CI 1.25–1.45) over 730 days of follow-up (P < 0.001), using 
identical covariables as above (Fig. 2). 
 
Discussion 
Previous studies have shown increased mortality in people with Type 2 diabetes who have 
higher HbA1c variability [4–8]. Although it is known that HbA1c variability increases 
microvascular complications in Type 1 diabetes there is no previous evidence of increased 
mortality in this group [10]. Our results demonstrate increased mortality and earlier hospital 
admission associated with HbA1c variability in Type 1 diabetes. 
There is no accepted standard measure of variability of HbA1c. We have chosen to use CV 
because this measure is calculated using both mean and SD. CV therefore intrinsically 
mitigates to some extent the influence of average HbA1c on variability. 
The potential mechanisms of our observations are uncertain. In vitro studies have shown that 
short-term glucose fluctuations induce more oxidative stress than continuous high glucose 
[13]. Endothelial dysfunction is precipitated due to the release of inflammatory cytokines 
progressing to increased carotid intimal thickness and increased left ventricular mass [14]. 
The impact of glucose variability and oxidative stress in humans is less clear [15,16]. 
Although some studies have shown a positive correlation, alternative studies have failed to 
find a link [13,17]. It must be remembered that these studies can only look at the effect of 
glucose variability over a short interval. Furthermore, there is no firm evidence that short-
term glucose variability progresses to longer term glucose variability. Therefore, short-term 
glucose fluctuations may be irrelevant when considering morbidity and mortality. 
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HbA1c variability could be a marker of variable treatment concordance. Patients with greater 
variability may lead more chaotic lifestyles and therefore have suboptimal management, for 
example, a higher risk of developing diabetic ketoacidosis if they do not engage [12]. Greater 
HbA1c variability is also associated with reduced medication compliance and the use of 
antipsychotics and glucocorticoids which may impair glycaemic control [6]. Other 
associations with greater HbA1c variability are more complex medical histories, lower quality 
of life, low socio-economic status and lack of peer support systems [6]. Therefore, perhaps 
these risk factors lead to higher levels of morbidity and mortality. 
Disease processes that could lead to both improvement or worsening of HbA1c variability are 
worth further consideration. These could act as confounding variables between HbA1c and 
mortality. An example is a hypothetical patient who develops renal failure and a change in 
HbA1c measurement due to reduced insulin clearance. 
The main strength of our study is analysis of an inclusive database with a large cohort of 
patients over a long observation. The main weakness is that we cannot be certain of 
causation. Further research is required to ascertain whether HbA1c variability causes poor 
health outcomes directly or whether confounding factors such as concurrent renal disease, 
smoking, social deprivation or use of lipid- and blood pressure-lowering medications might 
be influencing the observed increase in mortality. Unfortunately, robust data on these 
potential confounding factors was not available for analysis. Treatment with continuous 
subcutaneous insulin infusion (CSII) has been shown to reduce cardiovascular mortality [18]. 
As of June 2015, only 7.1% of adults with Type 1 diabetes in Scotland were using CSII 
treatment [19]. Over the time course of this study, this percentage will have been significantly 
lower. It is therefore unlikely that CSII usage would have had a major impact on outcomes. 
Analysis of whether HbA1c variability leads to increased incidence of specific causes of 
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death, for example diabetic ketoacidosis has not been carried out. It would be useful to 
analyse this in more detail in future studies. 
This is the first study to demonstrate a relationship between HbA1c variability and mortality 
in people with Type 1 diabetes. Our results may have clinical implications. Although 
guidelines stress the importance of tight glycaemic control, this may not be appropriate in 
some populations [20]. Rapid improvements in glucose control have been associated with 
worsening of clinical outcome. In an inpatient cardiothoracic population, improvement in 
glycaemic control, and potential increased HbA1c variability, led to worse outcome in patients 
with diabetes [21]. 
Perhaps glycaemic metrics beyond single time-point HbA1c could be implemented as more 
effective measures for assessing risk of an individual developing diabetes complications [22]. 
With progression of technology allowing direct monitoring of blood glucose fluctuations, 
assessment of the efficacy of diabetes mellitus treatment can move forward from HbA1c 
measurement as the sole marker of glycaemic control [23]. Even if HbA1c variability in Type 
1 diabetes has a non-causal association with poor outcomes it allows for effective risk 
stratification and identification for intervention. 
In conclusion, our results show that people with greater HbA1c variability have a higher rate 
of mortality and earlier hospital admission in Type 1 diabetes. Limiting HbA1c fluctuations 
over time may reduce these risks. It is important to note that people may have suboptimal 
control of their diabetes despite having a ‘well controlled’ HbA1c. Identification of patients 
with high variability of HbA1c may be beneficial by allowing for targeting of support and 
increased education by the specialist diabetes team. 
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FIGURE 1 Time to death over 47 months of follow-up for 6048 individuals with Type 1 diabetes. Solid line, 
individuals with an HbA1c coefficient of variation (CV) below the median value of 7.9. Dashed line, individuals 
with an HbA1c CV above the median value. 
FIGURE 2 Survival to first admission or death over 47 months for 6048 individuals with Type 1 diabetes. Solid 
line,  individuals with an HbA1c coefficient of variation (CV) below the median value of 7.9. Dashed line, 
individuals with an HbA1c CV above the median value. 
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Table 1 Characteristics of groups with HbA1c coefficient of variation (CV) above and below median value.  
 
 HbA1c CV
 < 7.9 ≥ 7.9 P-value 
n 3024 3024  
Mean age at 1 January 2013 (years)* 44.0 (16.9) 42.9 (18.5) < 0.01
Median no. of HbA1c measurements 
during run-in period† 
4 (3–5) 4 (3–5) 0.45 
Mean HbA1c during the run-in 
period (mmol/mol; %)† 
72.4; 8.8 (16.4) 74.8; 9 (17.1) < 0.01 
Median diabetes duration (years)* 19.0 (11.9–29.0) 16.2 (9.7–27.0) < 0.01 
No. of deaths during follow-up 
period 
168 246 < 0.01
No. of admissions or deaths during 
follow-up period 
693 865 < 0.01
Comparisons between groups were made using the Mann–Whitney U test. 
Values in parentheses are *SD or †IQR. 
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